Apidra U-100 Insulin (insulin glulisine)
Short-Acting Insulins Subcutaneous Vial (ML)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Insulin glulisine is a biosynthetic (rDNA origin), rapid-acting human insulin analog.
Insulin glulisine is a biosynthetic, rapid-acting insulin human analog that is prepared using recombinant DNA technology and a special laboratory strain of nonpathogenic Escherichia coli (K12). Insulin glulisine differs structurally from insulin human by the replacement of asparagine at position 3 on the B chain with lysine and by replacement of lysine at position 29 on the B chain with glutamic acid. These structural modifications result in a decreased tendency to form hexamers, improved monomer stability, and increased rate of absorption.
Insulin glulisine has pharmacologic effects comparable to those of insulin human, lowering blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production. Insulin glulisine also inhibits lipolysis and proteolysis and enhances protein synthesis. Results of clinical trials indicate that the glucose-lowering effect of insulin glulisine is approximately the same as that of insulin human on a unit-for-unit basis.
Following subcutaneous administration, insulin glulisine has a more rapid onset and shorter duration of action compared with insulin human (regular). After subcutaneous administration, the time to maximum concentration (Tmax) of insulin glulisine is 60 minutes (range: 40--120 minutes) in patients with type 1 diabetes mellitus and 100 minutes (range: 40--120 minutes) in patients with type 2 diabetes mellitus. The absolute bioavailability of insulin glulisine after subcutaneous administration is approximately 70%, regardless of injection area.
Interindividual and intraindividual variation in rate of absorption and consequently, the onset of action of insulins, including insulin glulisine, may occur based on site of injection, method of administration, tissue blood supply, temperature, and physical activity. After subcutaneous administration, the apparent half-life of insulin glulisine is 42 minutes. When given by intravenous infusion, the half-life of insulin glulisine is similar to that of insulin human (13 minutes versus 17 minutes, respectively).
The pharmacokinetics of insulin glulisine are similar in pediatric patients compared to adults. After subcutaneous injection of insulin glulisine, Japanese subjects had greater initial exposure (33%) compared to white subjects, although total exposure was similar. In obese subjects with a body mass index of 30--40 kg/m2, the more rapid onset of action and shorter duration of insulin glulisine relative to insulin human were maintained.
In patients with moderate or severe renal impairment, insulin glulisine exposure is increased and clearance is decreased compared to patients with normal renal function. The effects of hepatic impairment, gender, and smoking on the pharmacokinetics of insulin glulisine have not been studied.
USES: Insulin glulisine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke.
Insulin glulisine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin glulisine starts working faster and lasts for a shorter time than regular insulin.
It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product.
Generic name: insulin glulisine
Pronunciation: (IN-su-lin GLOO-lis-een)
Drug class: Short-Acting Insulins
Therapeutic class: Endocrine
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Apidra U-100 Insulin
Indications
The following indications are listed for Apidra U-100 Insulin:
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
Also known as: Adult Onset Diabetes, Adult Onset Diabetes Mellitus, Adult Onset Dm, Diabetes Mellitus Type 1, Diabetes Mellitus Type 2, Diabetes Mellitus Type Ii, Immune Mediated Diabetes Mellitus, Insulin Dependent Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus, Insulin-Dependent Dm, Juvenile Diabetes, Juvenile Onset Dm, Juvenile-Onset Diabetes, Juvenile-Onset Diabetes Mellitus, Ketosis-Prone Diabetes, Ketosis-Prone Diabetes Mellitus, Ketosis-Prone Dm, Ketosis-Resistant Diabetes Mellitus, Ketosis-Resistant Dm, Maturity Onset Diabetes, Maturity Onset Diabetes Mellitus, Non-Insulin Dependent Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus, Type I Diabetes Mellitus, Type Ii Diabetes Mellitus.
Dosing
Insulin glulisine and insulin human are equipotent on a unit-for-unit basis with regard to glucose-lowering activity (as determined following IV administration).
Dosage of insulin glulisine must be based on the results of blood glucose determinations, the patient's metabolic needs, and glycemic control goal and must be carefully individualized to obtain optimum therapeutic effect.
Insulin glulisine is administered by subcutaneous injection using a conventional insulin syringe or a prefilled insulin injection pen (SoloStar(R)). Prefilled insulin glulisine injection pens should be used with caution in patients with visual impairment who may rely on audible clicks to dial their dosage.
When the SoloStar(R) injection pen is used for subcutaneous injection of insulin glulisine, the accompanying labeling should be consulted for proper methods of assembly, administration, and care.
When used as a mealtime insulin to control postprandial hyperglycemia, insulin glulisine is administered within 15 minutes before a meal or 20 minutes after starting a meal by subcutaneous injection into the abdominal wall, thigh, or upper arm. A planned rotation of injection sites and injection sites within an area should be followed; injections should not be placed into areas of lipodystrophy or localized cutaneous amyloidosis.
Insulin glulisine administered by subcutaneous injection may be mixed with isophane insulin human (NPH); the drug should not be mixed with any other type of insulin. Whenever insulin glulisine is mixed with isophane insulin human, insulin glulisine should be drawn into the syringe first. The insulin mixture should be administered immediately after mixing; such mixtures should not be administered IV.
Insulin glulisine also is administered by continuous subcutaneous infusion using an external controlled-infusion device; the administration, use, and storage instructions provided by the device manufacturer should be followed . When used in an external infusion pump, insulin glulisine should not be diluted or mixed with any other insulins.
Insulin glulisine also is administered by IV infusion for glycemic control under appropriate medical supervision in a clinical setting. When administered IV, insulin glulisine should be diluted to a concentration of 0.05--1 unit/mL in 0.9% sodium chloride injection. Insulin glulisine is not compatible with, and should not be diluted in, dextrose or Ringer's injection. The manufacturer states that use of use of IV diluents other than 0.9% sodium chloride injection has not been studied and is not recommended. The manufacturer recommends use of polyvinyl chloride infusion bags. Diluted solutions of insulin glulisine for IV infusion should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Only clear and colorless solutions should be used; solutions should be discarded if they are cloudy or contain particulate matter. Diluted solutions of insulin glulisine in 0.9% sodium chloride injection for IV infusion are stable at room temperature for up to 48 hours.
Store unopened vials and prefilled injection pens of insulin glulisine in the original sealed carton in the refrigerator at 2--8degreesC until the expiration date; protect from light. Alternately, unopened vials and prefilled injection pens of insulin glulisine may be stored at room temperature (up to 25degreesC) for up to 28 days. Opened (in-use) vials of insulin glulisine may be stored in the refrigerator (at 2--8degreesC) or at room temperature (up to 25degreesC) for up to 28 days. Opened (in-use) vials of insulin glulisine used in an insulin pump may be stored for 48 hours up to 37degreesC; the insulin glulisine pump reservoir should be changed every 48 hours or according to the pump user manual, whichever is shorter. Open (in-use) injection pens of insulin glulisine may be stored at room temperature (up to 25degreesC) for up to 28 days but should not be refrigerated.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Agents Affecting Growth Hormone/Macimorelin
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Agents affecting growth hormone may impact the accuracy of the macimorelin diagnostic test.(1)
CLINICAL EFFECTS: Concurrent use of agents affecting growth hormone may impact the accuracy of the macimorelin diagnostic test.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The US manufacturer of macimorelin states concurrent use with agents affecting growth hormone may impact the accuracy of the macimorelin diagnostic test. Discontinue growth hormone products at least 1 week before administering the macimorelin diagnostic test. Sufficient washout time of drugs affecting growth hormone release prior to administration of macimorelin is recommended.(1) Agents affecting growth hormone include: - Drugs that directly affect the pituitary secretion of growth hormone (e.g. somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors) - Drugs that may transiently elevate growth hormone concentrations (e.g. clonidine, levodopa, insulin) - Drugs that may blunt the growth hormone response (e.g. muscarinic antagonists, anti-thyroid medications, growth hormone products)
DISCUSSION: Concurrent use of agents affecting growth hormone may impact the accuracy of the macimorelin diagnostic test.(1)
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Antidiabetic Agents/Gatifloxacin
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The exact mechanism is unknown.
CLINICAL EFFECTS: Concurrent use of gatifloxacin may result in hypoglycemia and/or hyperglycemia.(1-4) Hypoglycemia is more common during the first three days of concurrent therapy. Hyperglycemia is more common after the first three days of concurrent therapy.(2)
PREDISPOSING FACTORS: Elderly patients, especially those with decreased renal function may be predisposed to this interaction.(2)
PATIENT MANAGEMENT: Patients receiving concurrent gatifloxacin should be closely monitored for hypoglycemia during the first three days of concurrent therapy and for hyperglycemia after the first three days of concurrent therapy. Patients should be instructed to discontinue gatifloxacin if hypoglycemia or hyperglycemia occur.(2)
DISCUSSION: Hypoglycemia has been reported with gatifloxacin and glyburide(1,5,6) or glimepiride.(7) In a study in patients with type 2 diabetes mellitus, concurrent gatifloxacin (400 mg daily for 10 days) had no effect on the pharmacokinetics of glyburide (steady state daily regimen); however, pharmacodynamic interactions have been reported.(2) Health Canada has received 19 reports of hypoglycemia in patients taking gatifloxacin. Seventeen of these involved concurrent hypoglycemic agents. Health Canada has received 2 reports of hyperglycemia in patients taking gatifloxacin and hypoglycemic agents. Health Canada has received 2 reports of patients experiencing hypoglycemia and hyperglycemia during concurrent gatifloxacin and hypoglycemic agents.(3) In a study, 13 reports of dysglycemia were reported in patients taking gatifloxacin. Ten of these patients had diabetes mellitus and were on concurrent hypoglycemic agents. Of these ten patients, nine patients experienced hypoglycemia, while one patient experienced hyperglycemia.(8)
Insulin/Rosiglitazone
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The exact mechanism is unknown, but may be the result of additive fluid retention.(1,2)
CLINICAL EFFECTS: The concurrent use of rosiglitazone and insulin may increase the risk of edema, heart failure, and other cardiovascular effects such as myocardial infarction.(1,2)
PREDISPOSING FACTORS: Use in patients with NYHA Class I and II heart failure may increase the risk of other cardiovascular events.(1,2)
PATIENT MANAGEMENT: The US manufacturer of rosiglitazone states that concurrent use with insulin is not recommended.(1) If concurrent therapy is warranted, patients should be monitored for cardiovascular adverse events. If signs and symptoms of congestive heart failure develop, patients should be treated according to current standards of care. Consideration should be given to lowering the dosage of or discontinuing rosiglitazone.(2)
DISCUSSION: In a meta-analysis of 7 controlled, randomized, double-blind clinical trials in which patients were randomized to coadministration of rosiglitazone with insulin or insulin alone, the incidence of congestive heart failure in patients receiving concurrent rosiglitazone was 2.3%, compared with 1.0% in patients receiving insulin alone. More patients in the concurrent rosiglitazone group experienced myocardial infarctions, MACE (a composite of myocardial infarction, cardiovascular death, or stroke), cardiovascular deaths, and all-cause deaths than in the group receiving insulin alone.(1) In clinical trials, edema was reported in 14.7% of patients receiving concurrent rosiglitazone and insulin, compared with 5.4% on insulin alone or 4.8% on rosiglitazone alone.(1) In clinical trials, new onset or exacerbation of congestive heart failure occurred at rates of 1%, 2%, and 3%, respectively, in patients treated with insulin alone, insulin with 4 mg of rosiglitazone, and insulin with 8 mg of rosiglitazone.(1)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Antidiabetic Agents/Gymnema
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Gymnema has been shown to increase the number of insulin-secreting beta cells in animals. It has also been shown to increase the activity of enzymes responsible for glucose uptake and utilization and inhibit peripheral utilization of glucose.(1)
CLINICAL EFFECTS: Use of gymnema may result in decreased requirements of antidiabetic agents.(2-4)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Diabetic patients should be carefully monitored if gymnema is initiated or discontinued from concurrent therapy. The dosage of the patient's antidiabetic agent(s) may need to be adjusted.(2)
DISCUSSION: In a study in 22 non-insulin-dependent patients, patients had decreased blood glucose, glycosylated hemoglobin, and glycosylated plasma proteins during gymnema therapy. Patients were able to decrease the dosage of their conventional antidiabetic therapy and five patients were able to discontinue their conventional antidiabetic therapy.(3) In a study in 27 insulin-dependent patients, patients had decreased insulin requirements, fasting blood glucose, glycosylated hemoglobin, and glycosylated plasma protein levels.(4)
Antidiabetics/Epinephrine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Gluconeogenesis, glycogenolysis, and lipolysis are increased by epinephrine. Also, insulin secretion and glucose uptake by peripheral tissues are decreased by epinephrine.
CLINICAL EFFECTS: Increased blood glucose resulting in decreased effectiveness of the antidiabetic agent.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Caution when starting or stopping epinephrine in diabetic patients. Adjust the antidiabetic dose as needed based on blood glucose levels.
DISCUSSION: This interaction is likely to occur based upon well documented properties of the interacting drugs. However, there is individual variability in its occurrence.
Antidiabetics/Slt Ophth Non-Cardioselective Beta-Blockers
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia.(1,2)
CLINICAL EFFECTS: Diminished response to sulfonylureas and insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked.(1,2)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia.
DISCUSSION: A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo.(3) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(4) There have been case reports of hypoglycemia following the addition of ophthalmic timolol to a diabetic regimen.(5-7) Studies have shown that ophthalmic beta-blockers, especially the aqueous solution, have significant systemic absorption and do not undergo first-pass metabolism.(8,9)
Hypoglycemics; Insulin/Bupropion
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Bupropion can lower the seizure threshold and when given concurrently with other medications that also lower the threshold there is an increased risk of seizure. Concurrent use of hypoglycemics or insulin increases the risk of hypoglycemia which can result in seizures.(1,2)
CLINICAL EFFECTS: Concurrent use of bupropion and hypoglycemics or insulin may increase the risk of seizure.(1,2)
PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants an anorectics; a total daily dose of bupropion greater than 450 mg or single doses greater than 150 mg; rapid escalation of bupropion dosage; or with concomitant medications known to lower seizure threshold (antidepressants, antipsychotics, systemic steroids, theophylline).(1,2)
PATIENT MANAGEMENT: The use of bupropion in patients treated with oral hypoglycemic agents or insulin should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2) Single doses should not exceed 150 mg.(1,2) The maximum daily dose of bupropion should not exceed 300 mg for smoking cessation(2) or 450 mg for depression.(1)
DISCUSSION: Because of the risk of seizure from concurrent bupropion and other agents that lower seizure threshold, the manufacturer of bupropion states that the concurrent use of bupropion and oral hypoglycemic agents or insulin should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2)
Insulin/Carvedilol; Labetalol
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia.
CLINICAL EFFECTS: Diminished response to insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia.
DISCUSSION: A class effect of diminished glucose-lowering effects is expected with concurrent use of beta-blockers and insulin. It is prudent to monitor serum glucose closely in patients receiving beta-blocker therapy because symptoms of hypoglycemia may be masked. A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5 mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo. (1) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5 mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(2)
Insulin/Fenfluramine;Dexfenfluramine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Fenfluramine increases glucose uptake at the receptor site (ie, skeletal muscle).
CLINICAL EFFECTS: The hypoglycemic effect of insulin is increased.
PREDISPOSING FACTORS: Diabetes.
PATIENT MANAGEMENT: In diabetic patients receiving insulin, monitor blood glucose levels and observe the patient for signs of hypoglycemia when initiating therapy with fenfluramine and for symptoms of hyperglycemia when fenfluramine is discontinued.
DISCUSSION: When administered before meals or to fasting patients, fenfluramine has been found to have hypoglycemic action. Numerous reports have demonstrated fenfluramine to potentiate the hypoglycemic effect of insulin in diabetic patients.
Insulin/Pioglitazone
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism is unknown, but may be the result of additive fluid retention.(1,2)
CLINICAL EFFECTS: The concurrent use of pioglitazone with insulin may increase the risk of edema and heart failure.(1,2)
PREDISPOSING FACTORS: Specific risk factors for heart failure could not be determined. Patients with ongoing edema are more likely to have edema-associated adverse effects with combination therapy.(1)
PATIENT MANAGEMENT: Patients receiving concurrent therapy should be monitored for cardiovascular adverse events. If signs and symptoms of congestive heart failure develop, patients should be treated according to current standards of care. Consideration should be given to lowering the dosage of or discontinuing pioglitazone.(1,2)
DISCUSSION: In a clinical trial, two of 191 (1.1%) of patients receiving pioglitazone (15 mg) and insulin and two of 188 (1.1%) of patients receiving pioglitazone (30 mg) and insulin developed congestive heart failure. None of the patients receiving insulin alone developed congestive heart failure.(1)
Insulin/Selected Systemic Non-Cardioselective Beta-Blockers
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia. MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia.
CLINICAL EFFECTS: Diminished response to insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked. CLINICAL EFFECTS: Diminished response to insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked.
PREDISPOSING FACTORS: None determined. PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia. PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia.
DISCUSSION: A class effect of diminished glucose-lowering effects is expected with concurrent use of beta-blockers and insulin. It is prudent to monitor serum glucose closely in patients receiving beta-blocker therapy because symptoms of hypoglycemia may be masked. A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5 mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo. (1) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5 mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(2) DISCUSSION: A class effect of diminished glucose-lowering effects is expected with concurrent use of beta-blockers and insulin. It is prudent to monitor serum glucose closely in patients receiving beta-blocker therapy because symptoms of hypoglycemia may be masked. A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5 mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo. (1) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5 mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(2)
Selected Antidiabetic Agents/Chloroquine; Hydroxychloroquine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism is unknown. Chloroquine and hydroxychloroquine may increase insulin sensitivity by inhibiting insulin metabolism and inflammation and increasing cellular uptake of glucose and glycogen synthesis.(1,2) These effects may result in additive hypoglycemia with anti-diabetic agents.
CLINICAL EFFECTS: Concurrent use of chloroquine or hydroxychloroquine and antidiabetic agents may result in severe hypoglycemia.(3) Hypoglycemia can lead to coma.
PREDISPOSING FACTORS: Elderly patients, especially those with decreased renal function may be predisposed to this interaction.
PATIENT MANAGEMENT: Patients maintained on antidiabetic agents who require concurrent therapy with chloroquine or hydroxychloroquine should be closely monitored for hypoglycemia. A decrease in the dose of insulin or other anti-diabetic medications may be required. Patients should be advised of the risk and symptoms of hypoglycemia and to contact their doctor if hypoglycemia occurs.(3) Signs of hypoglycemia may include confusion, dizziness, feeling shaky, unusual hunger, headaches, irritability, pounding heart or very fast pulse, pale skin, sweating, trembling, weakness, or unusual anxiety.
DISCUSSION: Hydroxychloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening.(3) Concomitant hypoglycemic agents may increase the risk and/or severity of this effect. A 77 year old man who was stable on twice daily insulin suffered two episodes of hypoglycemic coma 2 weeks after starting prednisone 5 mg daily and hydroxychloroquine 400 mg daily for rheumatoid arthritis. His insulin dosage required a decrease of 37%.(4) Many studies have investigated the glucose-lowering effect of hydroxychloroquine. In a clinical trial of type II diabetics on maximal doses of sulfonylureas, addition of hydroxychloroquine lowered hemoglobin A1C (HbA1C) up to 1% more than placebo.(5) Another clinical trial of type II diabetics on metformin and glimepiride or gliclazide found that hydroxychloroquine 400 mg daily reduced fasting blood glucose (FBG), post-prandial glucose (PPG), and HbA1C to a similar degree as pioglitazone 15 mg daily at 24 weeks.(6) In a prospective observational study, 250 uncontrolled type II diabetics on metformin, glimepiride, pioglitazone, sitagliptin, and a SGLT-2 inhibitor received hydroxychloroquine 400 mg daily for 48 weeks. HbA1C decreased from 8.83% to 6.44%, FBG decreased by 40.78%, and PPG decreased by 58.95%. The doses of metformin were reduced by 50%, glimepiride and sitagliptin by 75%, and SGLT-2 inhibitors were discontinued in most patients.(7)
Selected Antidiabetic Agents/Selected Quinolones
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism is unknown.
CLINICAL EFFECTS: Concurrent use of quinolones and antidiabetic agents may result in severe hypoglycemia.(1-7) Hypoglycemia can lead to coma.
PREDISPOSING FACTORS: Elderly patients, especially those with decreased renal function may be predisposed to this interaction.(5)
PATIENT MANAGEMENT: Patients maintained on antidiabetic agents who require concurrent therapy with a quinolone should be closely monitored for hypoglycemia.(1-4) Patients should be instructed to discontinue quinolone use and contact their doctor if hypoglycemia occurs.(2,4) Signs of hypoglycemia may include confusion, dizziness, feeling shaky, unusual hunger, headaches, irritability, pounding heart or very fast pulse, pale skin, sweating, trembling, weakness, or unusual anxiety.
DISCUSSION: Hypoglycemia has been reported with concurrent ciprofloxacin and glyburide,(1,8,9) levofloxacin and glyburide,(2,10,11) norfloxacin and glyburide,(3) levofloxacin and glipizide (12) as well as levofloxacin and metformin-glibenclamide.(14) There has been one report of fatal hypoglycemia with concurrent levofloxacin and glyburide(9) and one of the above reports of hypoglycemia with concurrent levofloxacin and glyburide resulted in hypoxic brain injury.(11) A review of postmarketing adverse event data for the fluoroquinolones and hypoglycemic coma identified 56 reports in FAERS search from October 1987- April 2017 and 11 additional cases in the medical literature. Most patients had risk factors for hypoglycemia. 41 patients were taking one or more hypoglycemic drugs. 13 deaths occurred (some of these patients had renal insufficiency). 9 patients did not fully recover and had resultant disability.(13)
Selected Antidiabetics/Maois
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism by which MAO inhibitors affect carbohydrate metabolism and subsequent enhancement of the hypoglycemic action of insulin is not clear. The adrenergic response to hypoglycemia may be blocked by insulin release caused by MAOI's. In vitro studies have shown that MAO inhibitors are capable of both potentiating and inhibiting insulin release, depending on their concentrations. Stimulation of glucose-mediated insulin secretion is believed to be related to the MAO inhibitory effects of the drugs.
CLINICAL EFFECTS: The hypoglycemic response to both insulin and glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylurea may be increased.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Concurrent MAO inhibitor therapy for depression in a diabetic patient will often require reduction in dosage of the hypoglycemic agent because of enhanced hypoglycemic effects. Since the extent of the reaction is highly unpredictable, any diabetic patients receiving MAO inhibitors should be monitored for possible excessive hypoglycemia.
DISCUSSION: This interaction is likely to occur. The interaction between MAOIs and insulin is well documented. Additional documentation is necessary to confirm the potential interaction of MAOI's with other glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylureas but is expected to occur based on pharmacologic similarity. It may take several weeks for the full hypoglycemic effect of the MAOI to occur. Conversely, it may take several weeks for the effect to dissipate after stopping the MAOI. Furazolidone is known to be a monoamine oxidase inhibitor. Methylene blue, when administered intravenously, has been shown to reach sufficient concentrations to be a potent inhibitor of MAO-A. Metaxalone is a weak inhibitor of MAO.
Selected Antidiabetics/Safinamide
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism by which MAO inhibitors such as safinamide affect carbohydrate metabolism and subsequent enhancement of the hypoglycemic action of insulin is not clear. The adrenergic response to hypoglycemia may be blocked by insulin release caused by MAOI's. In vitro studies have shown that MAO inhibitors are capable of both potentiating and inhibiting insulin release, depending on their concentrations. Stimulation of glucose-mediated insulin secretion is believed to be related to the MAO inhibitory effects of the drugs.
CLINICAL EFFECTS: The hypoglycemic response to both insulin and glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylurea may be increased.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Concurrent MAO inhibitor therapy for depression in a diabetic patient will often require reduction in dosage of the hypoglycemic agent because of enhanced hypoglycemic effects. Since the extent of the reaction is highly unpredictable, any diabetic patients receiving MAO inhibitors should be monitored for possible excessive hypoglycemia.
DISCUSSION: This interaction is likely to occur. The interaction between MAOIs and insulin is well documented. Additional documentation is necessary to confirm the potential interaction of MAOI's with other glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylureas but is expected to occur based on pharmacologic similarity. It may take several weeks for the full hypoglycemic effect of the MAOI to occur. Conversely, it may take several weeks for the effect to dissipate after stopping the MAOI.
Contraindications
*Known hypersensitivity to insulin glulisine or to any ingredient in the formulation.
*Contraindicated during episodes of hypoglycemia.
There are no contraindication contraindications for this drug.
- Hypoglycemic disorder
- Disease of liver
- Hypokalemia
- Kidney disease with reduction in glomerular filtration rate (GFr)
Adverse reactions
The most common adverse effects of insulin glulisine are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritis, rash, and weight gain.
More Frequent
- Hypoglycemic disorder
Rare or Very Rare
- Anaphylaxis
- Hypersensitivity drug reaction
- Hypokalemia
- Localized cutaneous amyloidosis
Less Frequent
- Arthralgia
- Hypertension
- Influenza
- Injection site sequelae
- Lipodystrophy
- Pharyngitis
- Pruritus of skin
- Skin rash
- Upper respiratory infection
- Weight gain
Rare or Very Rare
- Peripheral edema
Precautions
No enhanced messaging available.
Safety and efficacy of insulin glulisine have been established in pediatric patients. Use of insulin glulisine in pediatric patients is supported by evidence from an active-controlled non-inferiority study in pediatric patients >=4 years of age with type 1 diabetes mellitus and from studies of adults with diabetes mellitus. The relative differences in pharmacokinetics and pharmacodynamics between insulin glulisine and insulin human (regular) in pediatric patients with type 1 diabetes mellitus were similar to those in healthy subjects and in adults with type 1 diabetes mellitus. In clinical trials, pediatric patients with type 1 diabetes mellitus treated with insulin glulisine or insulin lispro had a higher incidence of severe symptomatic hypoglycemia compared to adults with type 1 diabetes mellitus.
Available data have not established an association between insulin glulisine use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies in rats receiving up to 10 units/kg per day (2 times the average human dosage based on body surface area) and in rabbits receiving up to 1.5 units/kg per day (0.5 times the average human dosage based on body surface area), the effects were not different from those observed with insulin human.
Poorly controlled diabetes mellitus in pregnancy increases the maternal risk for diabetes ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications, and increases the fetal risk for major birth defects, still birth, and macrosomia-related morbidity. Hypoglycemia and hyperglycemia occur more frequently during pregnancy in patients with pre-gestational diabetes mellitus.
Available data from published literature suggests that human insulin products, including insulin glulisine, are transferred into human milk. No adverse effects have been reported in breast-fed infants. There is no information on the effects of insulin glulisine on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for insulin glulisine and any potential adverse effects on the breast-fed infant from the drug or from the underlying maternal condition.
The manufacturer of insulin glulisine makes no specific dosage recommendation for geriatric patients. The initial dosage, dosage increments, and maintenance dosage should be conservative in geriatric patients to reduce the risk of hypoglycemia.
In clinical trials in adults, 147 patients were >=65 years of age and 27 patients were >=75 years of age, the majority of whom had type 2 diabetes mellitus. No substantial differences in safety (i.e., incidence of hypoglycemia) and efficacy (i.e., changes in HbA1c) relative to younger adults, but increased sensitivity cannot be ruled out.
ICD codes
| Code | Type | Description |
|---|---|---|
| Type 1 diabetes mellitus | ||
| E10 | ICD10CM | Type 1 diabetes mellitus |
| E10.1 | ICD10CM | Type 1 diabetes mellitus with ketoacidosis |
| E10.10 | ICD10CM | Type 1 diabetes mellitus with ketoacidosis without coma |
| E10.11 | ICD10CM | Type 1 diabetes mellitus with ketoacidosis with coma |
| E10.2 | ICD10CM | Type 1 diabetes mellitus with kidney complications |
| E10.21 | ICD10CM | Type 1 diabetes mellitus with diabetic nephropathy |
| E10.22 | ICD10CM | Type 1 diabetes mellitus with diabetic chronic kidney disease |
| E10.29 | ICD10CM | Type 1 diabetes mellitus with other diabetic kidney complication |
| E10.3 | ICD10CM | Type 1 diabetes mellitus with ophthalmic complications |
| E10.31 | ICD10CM | Type 1 diabetes mellitus with unspecified diabetic retinopathy |
| E10.311 | ICD10CM | Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E10.319 | ICD10CM | Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema |
| E10.32 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy |
| E10.321 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E10.3211 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E10.3212 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E10.3213 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E10.3219 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E10.329 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
| E10.3291 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E10.3292 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E10.3293 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E10.3299 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E10.33 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy |
| E10.331 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E10.3311 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E10.3312 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E10.3313 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E10.3319 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E10.339 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
| E10.3391 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E10.3392 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E10.3393 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E10.3399 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E10.34 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy |
| E10.341 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E10.3411 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E10.3412 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E10.3413 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E10.3419 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E10.349 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
| E10.3491 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E10.3492 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E10.3493 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E10.3499 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E10.35 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy |
| E10.351 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E10.3511 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
| E10.3512 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
| E10.3513 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
| E10.3519 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E10.352 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E10.3521 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E10.3522 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E10.3523 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E10.3529 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E10.353 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E10.3531 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E10.3532 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E10.3533 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E10.3539 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E10.354 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E10.3541 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E10.3542 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E10.3543 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E10.3549 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E10.355 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy |
| E10.3551 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
| E10.3552 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
| E10.3553 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
| E10.3559 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
| E10.359 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema |
| E10.3591 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
| E10.3592 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
| E10.3593 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
| E10.3599 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E10.36 | ICD10CM | Type 1 diabetes mellitus with diabetic cataract |
| E10.37 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment |
| E10.37x1 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
| E10.37x2 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
| E10.37x3 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
| E10.37x9 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
| E10.39 | ICD10CM | Type 1 diabetes mellitus with other diabetic ophthalmic complication |
| E10.4 | ICD10CM | Type 1 diabetes mellitus with neurological complications |
| E10.40 | ICD10CM | Type 1 diabetes mellitus with diabetic neuropathy, unspecified |
| E10.41 | ICD10CM | Type 1 diabetes mellitus with diabetic mononeuropathy |
| E10.42 | ICD10CM | Type 1 diabetes mellitus with diabetic polyneuropathy |
| E10.43 | ICD10CM | Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E10.44 | ICD10CM | Type 1 diabetes mellitus with diabetic amyotrophy |
| E10.49 | ICD10CM | Type 1 diabetes mellitus with other diabetic neurological complication |
| E10.5 | ICD10CM | Type 1 diabetes mellitus with circulatory complications |
| E10.51 | ICD10CM | Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene |
| E10.52 | ICD10CM | Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene |
| E10.59 | ICD10CM | Type 1 diabetes mellitus with other circulatory complications |
| E10.6 | ICD10CM | Type 1 diabetes mellitus with other specified complications |
| E10.61 | ICD10CM | Type 1 diabetes mellitus with diabetic arthropathy |
| E10.610 | ICD10CM | Type 1 diabetes mellitus with diabetic neuropathic arthropathy |
| E10.618 | ICD10CM | Type 1 diabetes mellitus with other diabetic arthropathy |
| E10.62 | ICD10CM | Type 1 diabetes mellitus with skin complications |
| E10.620 | ICD10CM | Type 1 diabetes mellitus with diabetic dermatitis |
| E10.621 | ICD10CM | Type 1 diabetes mellitus with foot ulcer |
| E10.622 | ICD10CM | Type 1 diabetes mellitus with other skin ulcer |
| E10.628 | ICD10CM | Type 1 diabetes mellitus with other skin complications |
| E10.63 | ICD10CM | Type 1 diabetes mellitus with oral complications |
| E10.630 | ICD10CM | Type 1 diabetes mellitus with periodontal disease |
| E10.638 | ICD10CM | Type 1 diabetes mellitus with other oral complications |
| E10.64 | ICD10CM | Type 1 diabetes mellitus with hypoglycemia |
| E10.641 | ICD10CM | Type 1 diabetes mellitus with hypoglycemia with coma |
| E10.649 | ICD10CM | Type 1 diabetes mellitus with hypoglycemia without coma |
| E10.65 | ICD10CM | Type 1 diabetes mellitus with hyperglycemia |
| E10.69 | ICD10CM | Type 1 diabetes mellitus with other specified complication |
| E10.8 | ICD10CM | Type 1 diabetes mellitus with unspecified complications |
| E10.9 | ICD10CM | Type 1 diabetes mellitus without complications |
| E10.A | ICD10CM | Type 1 diabetes mellitus, presymptomatic |
| E10.A0 | ICD10CM | Type 1 diabetes mellitus, presymptomatic, unspecified |
| E10.A1 | ICD10CM | Type 1 diabetes mellitus, presymptomatic, stage 1 |
| E10.A2 | ICD10CM | Type 1 diabetes mellitus, presymptomatic, stage 2 |
| Type 2 diabetes mellitus | ||
| E08 | ICD10CM | Diabetes mellitus due to underlying condition |
| E08.0 | ICD10CM | Diabetes mellitus due to underlying condition with hyperosmolarity |
| E08.00 | ICD10CM | Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
| E08.01 | ICD10CM | Diabetes mellitus due to underlying condition with hyperosmolarity with coma |
| E08.1 | ICD10CM | Diabetes mellitus due to underlying condition with ketoacidosis |
| E08.10 | ICD10CM | Diabetes mellitus due to underlying condition with ketoacidosis without coma |
| E08.11 | ICD10CM | Diabetes mellitus due to underlying condition with ketoacidosis with coma |
| E08.2 | ICD10CM | Diabetes mellitus due to underlying condition with kidney complications |
| E08.21 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic nephropathy |
| E08.22 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease |
| E08.29 | ICD10CM | Diabetes mellitus due to underlying condition with other diabetic kidney complication |
| E08.3 | ICD10CM | Diabetes mellitus due to underlying condition with ophthalmic complications |
| E08.31 | ICD10CM | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy |
| E08.311 | ICD10CM | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema |
| E08.319 | ICD10CM | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema |
| E08.32 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy |
| E08.321 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema |
| E08.3211 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3212 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3213 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3219 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E08.329 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema |
| E08.3291 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3292 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3293 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3299 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E08.33 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy |
| E08.331 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema |
| E08.3311 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3312 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3313 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3319 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E08.339 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema |
| E08.3391 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3392 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3393 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3399 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E08.34 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy |
| E08.341 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema |
| E08.3411 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3412 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3413 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3419 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E08.349 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema |
| E08.3491 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3492 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3493 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3499 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E08.35 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy |
| E08.351 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema |
| E08.3511 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye |
| E08.3512 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye |
| E08.3513 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral |
| E08.3519 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E08.352 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E08.3521 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E08.3522 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E08.3523 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E08.3529 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E08.353 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E08.3531 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E08.3532 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E08.3533 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E08.3539 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E08.354 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E08.3541 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E08.3542 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E08.3543 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E08.3549 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E08.355 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy |
| E08.3551 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye |
| E08.3552 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye |
| E08.3553 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral |
| E08.3559 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye |
| E08.359 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema |
| E08.3591 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye |
| E08.3592 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye |
| E08.3593 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral |
| E08.3599 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E08.36 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic cataract |
| E08.37 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment |
| E08.37x1 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye |
| E08.37x2 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye |
| E08.37x3 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral |
| E08.37x9 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye |
| E08.39 | ICD10CM | Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication |
| E08.4 | ICD10CM | Diabetes mellitus due to underlying condition with neurological complications |
| E08.40 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified |
| E08.41 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic mononeuropathy |
| E08.42 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic polyneuropathy |
| E08.43 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy |
| E08.44 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic amyotrophy |
| E08.49 | ICD10CM | Diabetes mellitus due to underlying condition with other diabetic neurological complication |
| E08.5 | ICD10CM | Diabetes mellitus due to underlying condition with circulatory complications |
| E08.51 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene |
| E08.52 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene |
| E08.59 | ICD10CM | Diabetes mellitus due to underlying condition with other circulatory complications |
| E08.6 | ICD10CM | Diabetes mellitus due to underlying condition with other specified complications |
| E08.61 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic arthropathy |
| E08.610 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy |
| E08.618 | ICD10CM | Diabetes mellitus due to underlying condition with other diabetic arthropathy |
| E08.62 | ICD10CM | Diabetes mellitus due to underlying condition with skin complications |
| E08.620 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic dermatitis |
| E08.621 | ICD10CM | Diabetes mellitus due to underlying condition with foot ulcer |
| E08.622 | ICD10CM | Diabetes mellitus due to underlying condition with other skin ulcer |
| E08.628 | ICD10CM | Diabetes mellitus due to underlying condition with other skin complications |
| E08.63 | ICD10CM | Diabetes mellitus due to underlying condition with oral complications |
| E08.630 | ICD10CM | Diabetes mellitus due to underlying condition with periodontal disease |
| E08.638 | ICD10CM | Diabetes mellitus due to underlying condition with other oral complications |
| E08.64 | ICD10CM | Diabetes mellitus due to underlying condition with hypoglycemia |
| E08.641 | ICD10CM | Diabetes mellitus due to underlying condition with hypoglycemia with coma |
| E08.649 | ICD10CM | Diabetes mellitus due to underlying condition with hypoglycemia without coma |
| E08.65 | ICD10CM | Diabetes mellitus due to underlying condition with hyperglycemia |
| E08.69 | ICD10CM | Diabetes mellitus due to underlying condition with other specified complication |
| E08.8 | ICD10CM | Diabetes mellitus due to underlying condition with unspecified complications |
| E08.9 | ICD10CM | Diabetes mellitus due to underlying condition without complications |
| E09 | ICD10CM | Drug or chemical induced diabetes mellitus |
| E09.0 | ICD10CM | Drug or chemical induced diabetes mellitus with hyperosmolarity |
| E09.00 | ICD10CM | Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
| E09.01 | ICD10CM | Drug or chemical induced diabetes mellitus with hyperosmolarity with coma |
| E09.1 | ICD10CM | Drug or chemical induced diabetes mellitus with ketoacidosis |
| E09.10 | ICD10CM | Drug or chemical induced diabetes mellitus with ketoacidosis without coma |
| E09.11 | ICD10CM | Drug or chemical induced diabetes mellitus with ketoacidosis with coma |
| E09.2 | ICD10CM | Drug or chemical induced diabetes mellitus with kidney complications |
| E09.21 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic nephropathy |
| E09.22 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease |
| E09.29 | ICD10CM | Drug or chemical induced diabetes mellitus with other diabetic kidney complication |
| E09.3 | ICD10CM | Drug or chemical induced diabetes mellitus with ophthalmic complications |
| E09.31 | ICD10CM | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy |
| E09.311 | ICD10CM | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E09.319 | ICD10CM | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema |
| E09.32 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy |
| E09.321 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E09.3211 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E09.3212 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E09.3213 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E09.3219 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E09.329 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
| E09.3291 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E09.3292 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E09.3293 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E09.3299 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E09.33 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy |
| E09.331 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E09.3311 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E09.3312 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E09.3313 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E09.3319 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E09.339 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
| E09.3391 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E09.3392 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E09.3393 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E09.3399 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E09.34 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy |
| E09.341 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E09.3411 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E09.3412 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E09.3413 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E09.3419 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E09.349 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
| E09.3491 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E09.3492 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E09.3493 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E09.3499 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E09.35 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy |
| E09.351 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E09.3511 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
| E09.3512 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
| E09.3513 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
| E09.3519 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E09.352 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E09.3521 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E09.3522 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E09.3523 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E09.3529 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E09.353 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E09.3531 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E09.3532 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E09.3533 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E09.3539 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E09.354 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E09.3541 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E09.3542 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E09.3543 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E09.3549 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E09.355 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy |
| E09.3551 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
| E09.3552 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
| E09.3553 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
| E09.3559 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
| E09.359 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema |
| E09.3591 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
| E09.3592 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
| E09.3593 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
| E09.3599 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E09.36 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic cataract |
| E09.37 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment |
| E09.37x1 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
| E09.37x2 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
| E09.37x3 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
| E09.37x9 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
| E09.39 | ICD10CM | Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication |
| E09.4 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications |
| E09.40 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified |
| E09.41 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy |
| E09.42 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy |
| E09.43 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy |
| E09.44 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy |
| E09.49 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication |
| E09.5 | ICD10CM | Drug or chemical induced diabetes mellitus with circulatory complications |
| E09.51 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene |
| E09.52 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene |
| E09.59 | ICD10CM | Drug or chemical induced diabetes mellitus with other circulatory complications |
| E09.6 | ICD10CM | Drug or chemical induced diabetes mellitus with other specified complications |
| E09.61 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic arthropathy |
| E09.610 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy |
| E09.618 | ICD10CM | Drug or chemical induced diabetes mellitus with other diabetic arthropathy |
| E09.62 | ICD10CM | Drug or chemical induced diabetes mellitus with skin complications |
| E09.620 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic dermatitis |
| E09.621 | ICD10CM | Drug or chemical induced diabetes mellitus with foot ulcer |
| E09.622 | ICD10CM | Drug or chemical induced diabetes mellitus with other skin ulcer |
| E09.628 | ICD10CM | Drug or chemical induced diabetes mellitus with other skin complications |
| E09.63 | ICD10CM | Drug or chemical induced diabetes mellitus with oral complications |
| E09.630 | ICD10CM | Drug or chemical induced diabetes mellitus with periodontal disease |
| E09.638 | ICD10CM | Drug or chemical induced diabetes mellitus with other oral complications |
| E09.64 | ICD10CM | Drug or chemical induced diabetes mellitus with hypoglycemia |
| E09.641 | ICD10CM | Drug or chemical induced diabetes mellitus with hypoglycemia with coma |
| E09.649 | ICD10CM | Drug or chemical induced diabetes mellitus with hypoglycemia without coma |
| E09.65 | ICD10CM | Drug or chemical induced diabetes mellitus with hyperglycemia |
| E09.69 | ICD10CM | Drug or chemical induced diabetes mellitus with other specified complication |
| E09.8 | ICD10CM | Drug or chemical induced diabetes mellitus with unspecified complications |
| E09.9 | ICD10CM | Drug or chemical induced diabetes mellitus without complications |
| E11 | ICD10CM | Type 2 diabetes mellitus |
| E11.0 | ICD10CM | Type 2 diabetes mellitus with hyperosmolarity |
| E11.00 | ICD10CM | Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
| E11.01 | ICD10CM | Type 2 diabetes mellitus with hyperosmolarity with coma |
| E11.1 | ICD10CM | Type 2 diabetes mellitus with ketoacidosis |
| E11.10 | ICD10CM | Type 2 diabetes mellitus with ketoacidosis without coma |
| E11.11 | ICD10CM | Type 2 diabetes mellitus with ketoacidosis with coma |
| E11.2 | ICD10CM | Type 2 diabetes mellitus with kidney complications |
| E11.21 | ICD10CM | Type 2 diabetes mellitus with diabetic nephropathy |
| E11.22 | ICD10CM | Type 2 diabetes mellitus with diabetic chronic kidney disease |
| E11.29 | ICD10CM | Type 2 diabetes mellitus with other diabetic kidney complication |
| E11.3 | ICD10CM | Type 2 diabetes mellitus with ophthalmic complications |
| E11.31 | ICD10CM | Type 2 diabetes mellitus with unspecified diabetic retinopathy |
| E11.311 | ICD10CM | Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E11.319 | ICD10CM | Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema |
| E11.32 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy |
| E11.321 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E11.3211 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E11.3212 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E11.3213 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E11.3219 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E11.329 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
| E11.3291 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E11.3292 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E11.3293 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E11.3299 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E11.33 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy |
| E11.331 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E11.3311 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E11.3312 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E11.3313 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E11.3319 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E11.339 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
| E11.3391 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E11.3392 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E11.3393 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E11.3399 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E11.34 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy |
| E11.341 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E11.3411 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E11.3412 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E11.3413 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E11.3419 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E11.349 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
| E11.3491 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E11.3492 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E11.3493 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E11.3499 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E11.35 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy |
| E11.351 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E11.3511 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
| E11.3512 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
| E11.3513 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
| E11.3519 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E11.352 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E11.3521 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E11.3522 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E11.3523 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E11.3529 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E11.353 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E11.3531 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E11.3532 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E11.3533 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E11.3539 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E11.354 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E11.3541 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E11.3542 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E11.3543 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E11.3549 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E11.355 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy |
| E11.3551 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
| E11.3552 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
| E11.3553 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
| E11.3559 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
| E11.359 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema |
| E11.3591 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
| E11.3592 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
| E11.3593 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
| E11.3599 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E11.36 | ICD10CM | Type 2 diabetes mellitus with diabetic cataract |
| E11.37 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment |
| E11.37x1 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
| E11.37x2 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
| E11.37x3 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
| E11.37x9 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
| E11.39 | ICD10CM | Type 2 diabetes mellitus with other diabetic ophthalmic complication |
| E11.4 | ICD10CM | Type 2 diabetes mellitus with neurological complications |
| E11.40 | ICD10CM | Type 2 diabetes mellitus with diabetic neuropathy, unspecified |
| E11.41 | ICD10CM | Type 2 diabetes mellitus with diabetic mononeuropathy |
| E11.42 | ICD10CM | Type 2 diabetes mellitus with diabetic polyneuropathy |
| E11.43 | ICD10CM | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E11.44 | ICD10CM | Type 2 diabetes mellitus with diabetic amyotrophy |
| E11.49 | ICD10CM | Type 2 diabetes mellitus with other diabetic neurological complication |
| E11.5 | ICD10CM | Type 2 diabetes mellitus with circulatory complications |
| E11.51 | ICD10CM | Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene |
| E11.52 | ICD10CM | Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene |
| E11.59 | ICD10CM | Type 2 diabetes mellitus with other circulatory complications |
| E11.6 | ICD10CM | Type 2 diabetes mellitus with other specified complications |
| E11.61 | ICD10CM | Type 2 diabetes mellitus with diabetic arthropathy |
| E11.610 | ICD10CM | Type 2 diabetes mellitus with diabetic neuropathic arthropathy |
| E11.618 | ICD10CM | Type 2 diabetes mellitus with other diabetic arthropathy |
| E11.62 | ICD10CM | Type 2 diabetes mellitus with skin complications |
| E11.620 | ICD10CM | Type 2 diabetes mellitus with diabetic dermatitis |
| E11.621 | ICD10CM | Type 2 diabetes mellitus with foot ulcer |
| E11.622 | ICD10CM | Type 2 diabetes mellitus with other skin ulcer |
| E11.628 | ICD10CM | Type 2 diabetes mellitus with other skin complications |
| E11.63 | ICD10CM | Type 2 diabetes mellitus with oral complications |
| E11.630 | ICD10CM | Type 2 diabetes mellitus with periodontal disease |
| E11.638 | ICD10CM | Type 2 diabetes mellitus with other oral complications |
| E11.64 | ICD10CM | Type 2 diabetes mellitus with hypoglycemia |
| E11.641 | ICD10CM | Type 2 diabetes mellitus with hypoglycemia with coma |
| E11.649 | ICD10CM | Type 2 diabetes mellitus with hypoglycemia without coma |
| E11.65 | ICD10CM | Type 2 diabetes mellitus with hyperglycemia |
| E11.69 | ICD10CM | Type 2 diabetes mellitus with other specified complication |
| E11.8 | ICD10CM | Type 2 diabetes mellitus with unspecified complications |
| E11.9 | ICD10CM | Type 2 diabetes mellitus without complications |
| E13 | ICD10CM | Other specified diabetes mellitus |
| E13.0 | ICD10CM | Other specified diabetes mellitus with hyperosmolarity |
| E13.00 | ICD10CM | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
| E13.01 | ICD10CM | Other specified diabetes mellitus with hyperosmolarity with coma |
| E13.1 | ICD10CM | Other specified diabetes mellitus with ketoacidosis |
| E13.10 | ICD10CM | Other specified diabetes mellitus with ketoacidosis without coma |
| E13.11 | ICD10CM | Other specified diabetes mellitus with ketoacidosis with coma |
| E13.2 | ICD10CM | Other specified diabetes mellitus with kidney complications |
| E13.21 | ICD10CM | Other specified diabetes mellitus with diabetic nephropathy |
| E13.22 | ICD10CM | Other specified diabetes mellitus with diabetic chronic kidney disease |
| E13.29 | ICD10CM | Other specified diabetes mellitus with other diabetic kidney complication |
| E13.3 | ICD10CM | Other specified diabetes mellitus with ophthalmic complications |
| E13.31 | ICD10CM | Other specified diabetes mellitus with unspecified diabetic retinopathy |
| E13.311 | ICD10CM | Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E13.319 | ICD10CM | Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema |
| E13.32 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy |
| E13.321 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E13.3211 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E13.3212 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E13.3213 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E13.3219 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E13.329 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
| E13.3291 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E13.3292 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E13.3293 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E13.3299 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E13.33 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy |
| E13.331 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E13.3311 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E13.3312 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E13.3313 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E13.3319 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E13.339 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
| E13.3391 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E13.3392 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E13.3393 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E13.3399 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E13.34 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy |
| E13.341 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E13.3411 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E13.3412 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E13.3413 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E13.3419 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E13.349 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
| E13.3491 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E13.3492 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E13.3493 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E13.3499 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E13.35 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy |
| E13.351 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E13.3511 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
| E13.3512 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
| E13.3513 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
| E13.3519 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E13.352 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E13.3521 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E13.3522 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E13.3523 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E13.3529 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E13.353 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E13.3531 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E13.3532 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E13.3533 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E13.3539 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E13.354 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E13.3541 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E13.3542 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E13.3543 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E13.3549 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E13.355 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy |
| E13.3551 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
| E13.3552 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
| E13.3553 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
| E13.3559 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
| E13.359 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema |
| E13.3591 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
| E13.3592 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
| E13.3593 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
| E13.3599 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E13.36 | ICD10CM | Other specified diabetes mellitus with diabetic cataract |
| E13.37 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment |
| E13.37x1 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
| E13.37x2 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
| E13.37x3 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
| E13.37x9 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
| E13.39 | ICD10CM | Other specified diabetes mellitus with other diabetic ophthalmic complication |
| E13.4 | ICD10CM | Other specified diabetes mellitus with neurological complications |
| E13.40 | ICD10CM | Other specified diabetes mellitus with diabetic neuropathy, unspecified |
| E13.41 | ICD10CM | Other specified diabetes mellitus with diabetic mononeuropathy |
| E13.42 | ICD10CM | Other specified diabetes mellitus with diabetic polyneuropathy |
| E13.43 | ICD10CM | Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E13.44 | ICD10CM | Other specified diabetes mellitus with diabetic amyotrophy |
| E13.49 | ICD10CM | Other specified diabetes mellitus with other diabetic neurological complication |
| E13.5 | ICD10CM | Other specified diabetes mellitus with circulatory complications |
| E13.51 | ICD10CM | Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene |
| E13.52 | ICD10CM | Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene |
| E13.59 | ICD10CM | Other specified diabetes mellitus with other circulatory complications |
| E13.6 | ICD10CM | Other specified diabetes mellitus with other specified complications |
| E13.61 | ICD10CM | Other specified diabetes mellitus with diabetic arthropathy |
| E13.610 | ICD10CM | Other specified diabetes mellitus with diabetic neuropathic arthropathy |
| E13.618 | ICD10CM | Other specified diabetes mellitus with other diabetic arthropathy |
| E13.62 | ICD10CM | Other specified diabetes mellitus with skin complications |
| E13.620 | ICD10CM | Other specified diabetes mellitus with diabetic dermatitis |
| E13.621 | ICD10CM | Other specified diabetes mellitus with foot ulcer |
| E13.622 | ICD10CM | Other specified diabetes mellitus with other skin ulcer |
| E13.628 | ICD10CM | Other specified diabetes mellitus with other skin complications |
| E13.63 | ICD10CM | Other specified diabetes mellitus with oral complications |
| E13.630 | ICD10CM | Other specified diabetes mellitus with periodontal disease |
| E13.638 | ICD10CM | Other specified diabetes mellitus with other oral complications |
| E13.64 | ICD10CM | Other specified diabetes mellitus with hypoglycemia |
| E13.641 | ICD10CM | Other specified diabetes mellitus with hypoglycemia with coma |
| E13.649 | ICD10CM | Other specified diabetes mellitus with hypoglycemia without coma |
| E13.65 | ICD10CM | Other specified diabetes mellitus with hyperglycemia |
| E13.69 | ICD10CM | Other specified diabetes mellitus with other specified complication |
| E13.8 | ICD10CM | Other specified diabetes mellitus with unspecified complications |
| E13.9 | ICD10CM | Other specified diabetes mellitus without complications |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.